MX2024010980A - Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor - Google Patents
Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayorInfo
- Publication number
- MX2024010980A MX2024010980A MX2024010980A MX2024010980A MX2024010980A MX 2024010980 A MX2024010980 A MX 2024010980A MX 2024010980 A MX2024010980 A MX 2024010980A MX 2024010980 A MX2024010980 A MX 2024010980A MX 2024010980 A MX2024010980 A MX 2024010980A
- Authority
- MX
- Mexico
- Prior art keywords
- aticaprant
- depressive disorder
- major depressive
- amorphous
- treatment
- Prior art date
Links
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 title abstract 6
- 229940121408 aticaprant Drugs 0.000 title abstract 6
- 208000024714 major depressive disease Diseases 0.000 title abstract 5
- 208000007415 Anhedonia Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317475P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052088 WO2023170550A1 (en) | 2022-03-07 | 2023-03-06 | Polymorph forms of aticaprant for use in treating major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010980A true MX2024010980A (es) | 2024-12-06 |
Family
ID=85706849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010980A MX2024010980A (es) | 2022-03-07 | 2024-09-06 | Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| ES2189759T3 (es) | 1999-05-12 | 2003-07-16 | Hoffmann La Roche | Derivados de imidazoiacepina. |
| US20020052365A1 (en) | 2000-10-05 | 2002-05-02 | Mohler Hanns | Selective anxiolytic therapeutic agents |
| JP2004518654A (ja) | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| WO2003082832A2 (en) | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| PT2208727E (pt) | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| WO2004080968A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
| CN1890208A (zh) | 2003-12-12 | 2007-01-03 | 伊莱利利公司 | 类鸦片受体拮抗剂 |
| BRPI0417714A (pt) | 2003-12-22 | 2007-03-20 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| JP2007528898A (ja) | 2004-03-12 | 2007-10-18 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| AU2005222640A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| US7378448B2 (en) | 2004-03-15 | 2008-05-27 | Eli Lilly And Company | Diphenylether amide derivatives as opioid receptor antagonists |
| WO2005090303A1 (en) | 2004-03-15 | 2005-09-29 | Eli Lilly And Company | 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| US8551986B2 (en) | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| PL2001456T3 (pl) | 2006-04-04 | 2010-05-31 | Emodys Gmbh | Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
| MX2009002527A (es) | 2006-09-08 | 2009-03-20 | Pfizer Prod Inc | Derivados de eter diarilico y usos de los mismos. |
| US7709522B2 (en) | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| US20130303497A1 (en) | 2010-08-05 | 2013-11-14 | Conrig Pharma Aps | Deuterated 5-ht1a receptor agonists |
| WO2013086496A2 (en) | 2011-12-09 | 2013-06-13 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| CA2933733A1 (en) | 2013-12-20 | 2015-06-25 | Connie Sanchez Morillo | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
| US10377698B2 (en) | 2015-03-30 | 2019-08-13 | University Of Innsbruck | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production |
| WO2016191763A2 (en) | 2015-05-28 | 2016-12-01 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| EP3468540A4 (en) | 2016-06-13 | 2020-03-18 | Board Of Regents Of the University Of Texas System | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| AU2017325870B2 (en) | 2016-09-16 | 2021-07-22 | Research Traingle Institute | Tetrahydroisoquinoline kappa opioid antagonists |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| DK3596069T3 (da) | 2017-03-17 | 2022-08-01 | Scripps Research Inst | Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil |
| SG10201802129QA (en) | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US20190255036A1 (en) | 2018-02-16 | 2019-08-22 | Alexander Kariman | Compound and method for reducing neuropathic pain and depression |
| US11820835B2 (en) | 2018-03-23 | 2023-11-21 | University Of Kansas | Cyclic tetrapeptide analogs |
| US11491144B2 (en) | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| US11103171B2 (en) | 2018-10-23 | 2021-08-31 | BlackThor Therapeutics, Ine. | Systems and methods for screening, diagnosing, and stratifying patients |
| US20200171025A1 (en) | 2018-11-29 | 2020-06-04 | Srinivasa Rao Parella | Pharmaceutical composition comprising brexpiprazole and process for preparation thereof |
| US11266627B1 (en) * | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| WO2022234457A1 (en) * | 2021-05-04 | 2022-11-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| EP4489748A1 (en) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
-
2023
- 2023-03-06 CN CN202380038808.6A patent/CN119156211A/zh active Pending
- 2023-03-06 CA CA3254365A patent/CA3254365A1/en active Pending
- 2023-03-06 WO PCT/IB2023/052088 patent/WO2023170550A1/en not_active Ceased
- 2023-03-06 US US18/178,961 patent/US11998524B2/en active Active
- 2023-03-06 AU AU2023232536A patent/AU2023232536A1/en active Pending
- 2023-03-06 TW TW112108148A patent/TW202345796A/zh unknown
- 2023-03-06 KR KR1020247033176A patent/KR20240156409A/ko active Pending
- 2023-03-06 IL IL315409A patent/IL315409A/en unknown
- 2023-03-06 JP JP2024553358A patent/JP2025508051A/ja active Pending
- 2023-03-06 EP EP23712343.5A patent/EP4489747A1/en active Pending
-
2024
- 2024-05-31 US US18/679,720 patent/US12171743B2/en active Active
- 2024-09-02 CL CL2024002627A patent/CL2024002627A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0197A patent/JOP20240197A1/ar unknown
- 2024-09-06 MX MX2024010980A patent/MX2024010980A/es unknown
- 2024-09-06 CO CONC2024/0012158A patent/CO2024012158A2/es unknown
- 2024-12-23 US US18/991,891 patent/US20250325515A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250325515A1 (en) | 2025-10-23 |
| CO2024012158A2 (es) | 2024-09-30 |
| US20230277499A1 (en) | 2023-09-07 |
| JOP20240197A1 (ar) | 2024-09-05 |
| TW202345796A (zh) | 2023-12-01 |
| US20240316003A1 (en) | 2024-09-26 |
| US12171743B2 (en) | 2024-12-24 |
| AU2023232536A1 (en) | 2024-10-24 |
| CN119156211A (zh) | 2024-12-17 |
| EP4489747A1 (en) | 2025-01-15 |
| CA3254365A1 (en) | 2023-09-14 |
| WO2023170550A1 (en) | 2023-09-14 |
| IL315409A (en) | 2024-11-01 |
| KR20240156409A (ko) | 2024-10-29 |
| US11998524B2 (en) | 2024-06-04 |
| CL2024002627A1 (es) | 2025-01-24 |
| JP2025508051A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012158A2 (es) | Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| CL2025001818A1 (es) | Uso de aflibercept para tratar o prevenir degeneración macular neovascular relacionada con la edad. | |
| MX2022015216A (es) | Compuestos de pladienolida y su uso. | |
| CL2021003317A1 (es) | Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula. | |
| EA201991933A1 (ru) | Лечение гингивита | |
| CO2024017693A2 (es) | Regímenes de dosis para tratamiento de infección de dengue | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| EP3922264A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| MX2024005220A (es) | Endoxifeno para el tratamiento del cancer. | |
| MX2024007301A (es) | Peptidos y metodos para usar en el tratamiento del dolor. | |
| MX2015015379A (es) | Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. | |
| MX2024007250A (es) | Coacervados complejos de lactoferrina y osteopontina. | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
| WO2020061067A8 (en) | Compositions and methods for treating bone injury | |
| MX2021000207A (es) | Regímenes de dosificación para el tratamiento de daños en los tejidos asociados a la hipoxia. | |
| AR128566A1 (es) | Combinaciones de fármacos y métodos para tratar el cáncer de ovario | |
| CL2021002853A1 (es) | Composición para la prevención o el tratamiento de la caída del cabello que incluye hapln1 |